The following NICE topics have been allocated to the ScHARR Technology Appraisal Group (ScHARR-TAG) and work will start soon:
Rivaroxaban (Xarelto) for the prevention of venous thromboembolism in people
hospitalised for acute medical conditions
hospitalised for acute medical conditions
Rivaroxaban (Xarelto) for deep vein thrombosis (symptomatic) and the prevention of
recurrent deep vein thrombosis and pulmonary embolismBoth are single technology appraisals. For further details, contact Eva Kaltenthaler or Matt Stevenson.
recurrent deep vein thrombosis and pulmonary embolismBoth are single technology appraisals. For further details, contact Eva Kaltenthaler or Matt Stevenson.